BERLIN (Reuters) -German pharma company Bayer reported positive study results for its anticoagulant asundexian on Sunday, two years after a research setback for the promising blood thinner candidate.
In a Phase III study, a daily dose of 50 milligrams significantly reduced the risk of ischemic stroke compared with a placebo, Bayer said.
Detailed results from the OCEANIC-STROKE study will be presented at an upcoming scientific congress, said Bayer.
Bayer added that it plans to speak with health authorities worldwide in preparation for the submission of marketing authorisation applications.
Bayer had originally predicted that asundexian would have peak sales potential of more than 5 billion euros ($5.76 billion) - more than any of its other drugs.
At the end of 2023, the company had a major setback with the drug after it failed in a pivotal clinical trial involving patients with atrial fibrillation and a risk of stroke.
($1 = 0.8687 euros)
(Reporting by Joern Poltz. Writing by Miranda Murray. Editing by Jane Merriman)
LATEST POSTS
- 1
Agricultural drones are taking off globally, saving farmers time and money - 2We may have less control over how long we live than previously thought
- 3Antimatter took to the road for the very first time. Here’s why it matters
- 4Best Internet based Course for Learning Another Dialect: Which Stage Do You Like?
- 5Artemis 2 astronauts see Earth in the rear-view mirror | Space photo of the day for April 3, 2026
- Exploring the Market: Unsold Rams May Be Less expensive Than You Naturally suspect
- Vote in favor of Your Number one kind of pie
- Outside Lovers' Decision: Favored Climbing Rucksacks
- KJ Apa stars as Jimmy Stewart in new biopic: See his transformation
- These Cities Led Global Jet-Setting In 2025, According To New Data
- Discussion on deployment of foreign troops ongoing, two sources tell 'Post'
- The Tradition of Stone: A Gander at Notable Structures Through the Ages
- FBI arrests Brian Cole Jr. in Jan. 6 pipe bomb investigation, ending 5-year hunt
- 6 Fun Urban areas For Seniors To Travel
